Identification of novel targets for immunotherapies in subsets of patients with diffuse large B‐cell lymphoma (<scp>DLBCL</scp>)-Reference-Cited by-同舟云学术

Identification of novel targets for immunotherapies in subsets of patients with diffuse large B‐cell lymphoma (DLBCL)

Published:2023-11-14 Issue: Volume: Page:
ISSN:0007-1048
Container-title:British Journal of Haematology
language:en
Short-container-title:Br J Haematol

Author:

Heini Alexander D.¹,Bacher Ulrike²^ORCID,Pabst Thomas¹^ORCID

Affiliation:

1. Department of Medical Oncology Inselspital, Bern University Hospital Bern Switzerland

2. Department of Hematology and Central Hematology Laboratory, Inselspital Bern University Hospital Bern Switzerland

Abstract

Personalized treatment options for subsets of patients with DLBCL are beginning to emerge. Caracciolo et al. explore UMG1, an epitope of CD43 as a potential target for certain patients with DLBCL, and demonstrate promising preclinical activity of an Anti‐UMG1‐antibody.Commentary on: Caracciolo et al. UMG1/CD3ε‐bispecific T‐cell engager (BTCE) redirects T‐cell cytotoxicity against diffuse large B‐cell lymphoma (DLBCL). Br J Haematol 2023 (Online ahead of print). doi: 10.1111/bjh.19183.

Publisher

Wiley

Subject

Hematology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/bjh.19195

Reference10 articles.

1. CAR T-Cell Persistence Correlates with Improved Outcome in Patients with B-Cell Lymphoma

2. CD43 expression is associated with inferior survival in the non-germinal centre B-cell subgroup of diffuse large B-cell lymphoma

3. Targeting CD43 optimizes cancer immunotherapy through reinvigorating antitumor immune response in colorectal cancer

4. UMG1/CD3ε‐bispecific T cell engager (BTCE) redirects T‐ cell cytotoxicity against diffuse large B cell lymphoma (DLBCL);Caracciolo D;Br J Haematol,2023

5. BCL2 expression in DLBCL: reappraisal of immunohistochemistry with new criteria for therapeutic biomarker evaluation